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Abstract 
Patients with marked calcification of the basal ganglia and cerebellum have traditionally 
been referred to as having Fahr’s disease, but the nomenclature has been criticized for 
including heterogeneous etiology. We describe 3 patients with idiopathic bilateral 
striatopallidodentate calcinosis (IBSPDC). The patients were a 24-year-old man with 
mental deterioration, a 57-year-old man with parkinsonism and dementia, and a 76-year-
old woman with dementia and mild parkinsonism. The former 2 patients showed severe 
calcification of the basal ganglia and cerebellum, and the latter patient showed severe 
calcification of the cerebellum. We found significantly increased levels of copper (Cu), 
zinc (Zn), iron (Fe) and magnesium (Mg), using inductively coupled plasma mass 
spectrometry in the CSF of all these 3 patients. The increased levels of Cu, Zn, Fe and Mg 
reflect the involvement of metabolism of several metals and/or metal-binding proteins 
during the progression of IBSPDC. More numerous patients with IBSPDC should be 
examined in other races to clarify the common mechanism of the disease and to 
investigate the specific treatment. 
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Introduction 
Mild calcification of the basal ganglia is sometimes seen, especially in the elderly. Some 
patients with marked calcification of the basal ganglia and cerebellum have been reported 
to be associated with hypoparathyroidism. Most other idiopathic cases have traditionally 
been referred to as having Fahr’s disease, but the nomenclature has been criticized for 
including a heterogeneous etiology and the disease has presented as a clinically complex 
syndrome. The patients have not been clearly demonstrated to exhibit any endocrine, 
metabolic or genetic disorder [1, 2]. The pathophysiological mechanism remains to be 
elucidated and there is no clue for the treatment. The disease is thus being referred to by 
some as idiopathic bilateral striatopallidodentate calcinosis (IBSPDC). Inductively 
coupled plasma mass spectrometry (ICP-MS) can measure the levels of several metals in a 
small amount of CSF [3]. We have measured those of Japanese patients with IBSPDC to 
clarify the pathophysiological features of the disease. 
Case Reports 
Patient 1 
A 24-year-old man was hospitalized for gait and speech disturbance. He had been diagnosed with 
Fahr’s disease when 15 years old in a hospital and his IQ was 79. On admission, neurological 
examination revealed mental deterioration (IQ 69), exaggerated deep tendon reflexes, mild rigidity on 
the right, and limb and truncal ataxia. CT showed a striking high density area in the basal ganglia and 
dentate nuclei and revealed progression with age (fig. 1a). No abnormal findings were detected in the 
blood tests including metals [calcium (Ca), iron (Fe), copper (Cu), zinc (Zn), magnesium (Mg) and 
manganese (Mn)], in Ca metabolism including parathyroid hormone and the Ellsworth-Howard test, 
and in routine CSF studies.  
Patient 2 
A 57-year-old man was hospitalized for dementia, bradykinesia, and gait disturbance. He showed 
parkinsonism at age 50 and mental deterioration since age 55. Neurological examination revealed 
dementia, slurred speech, limb ataxia, rigidity, bradykinesia and truncal ataxia. Interestingly, L-DOPA 
led to a slight improvement in symptoms. He showed similar CT findings as patient 1 (fig. 1b), diabetes 
mellitus, and no other abnormal findings either in the above-mentioned tests. 
Patient 3 
A 76-year-old woman came to our hospital for dementia. Neurological examination revealed 
dementia and mild parkisonism. CT showed a striking high density area in the dentate nuclei, and a 
moderate area in the basal ganglia and border of the cortex and white matter of the parietal lobe (fig. 
1c). No abnormal findings were detected in the above-mentioned tests. 
None of the 3 patients had a skeletal structural abnormality or a family history of IBSPDC. Analysis 
of the levels of Ca, Fe, Cu, Zn, Mg, and Mn in the scalp hair showed no specific findings in the 3 patients 
using a commercially-available ICP-MS method (La Belle Vie Inc., Tokyo, Japan).  
Metals in CSF Analysis 
CSF samples were obtained from 3 patients with IBSPDC and 15 controls (9 females and 6 males, age 
from 22 to 81 years with a mean of 52 years). CSF samples were nebulized with perhydroxyl-nitrate, and 
the levels of metals (Fe, Cu, Zn, Mg, and Mn) were measured using ICP-MS (HP4500, Agilent 
Technologies, Japan). Scandium (Sc), yttrium (Y) and thallium (Tl) were added to samples as internal 
standards. The concentrations of the elements were normalized by the internal standards. The level of  
Case Rep Neurol 2010;2:46–51 
DOI: 10.1159/000313920 
Published online: May 7, 2010  © 2010 S. Karger AG, Basel 
ISSN 1662–680X 
www.karger.com/crn 
 
 
48
Ca in the CSF was measured by colorimetry using o-cresolphthalein-complexone (o-CPC) for 
appropriate means. This study was approved by the Ethics Committee of the Gifu University Graduate 
School of Medicine.  
Results 
The levels of Cu, Zn, Fe, and Mg were significantly increased by 3.7, 2.5, 1.9, and 1.6 
times of control levels, respectively. Statistical analysis using Mann-Whitney U test 
showed significant difference (p < 0.01) in the levels of Cu, Fe and Mg, and significant 
difference (p < 0.05) in that of Zn, but the levels of Ca (1.1 times) and Mn (0.9 times) in 
the CSF of all 3 cases with IBSPDC were not significantly different from those of controls 
(table 1 and fig. 2) 
Discussion 
Chemical analyses of brain stones in the striopallidodental system has shown high 
levels of Ca and other metals, such as Fe, Mg, Cu, Zn, Mn, lead, and aluminium [4, 5]. 
However, there is no apparent explanation for the accumulation of calcium and other 
metals. The pathophysiological features of Fahr’s disease thus remain to be elucidated. 
The term ‘Fahr’s disease’ has various entities including familial and secondary cases. As 
the concept of Fahr’s disease may encompass diseases derived from different genetic or 
environmental etiologies in the region, we prefer the term ‘IBSPDC’ to ‘Fahr’s disease’. In 
Japan, elderly patients with dementia and calcification of the basal ganglia were reported 
to show diffuse neurofibrillary tangles and absence of senile plaques in the pathology [6, 
7]. Patients 2 and 3 are considered to be included in this category. We presented 3 
clinically idiopathic cases of IBSPDC with variable clinical characteristics and ages. 
ICP-MS can measure the level of several metals in a small amount of CSF (less than 1 
ml). ICP-MS is more sensitive and accurate than traditional colorimetery and the atomic 
absorption spectrophotometry method for the measurement of several metals such as Cu, 
Zn, Mg, except for that of Ca.  
Generally, the high density of the basal ganglia and cerebellum in CT images has been 
thought to be mainly associated with calcification. However, a disorder of Ca metabolism 
has not been demonstrated in IBSPDC. Only one preliminary study reported rather 
decreased levels of Ca in the CSF in Fahr’s disease, contrary to our expectations [8]. Our 3 
cases with IBSPDC showed various ages and clinical presentation, but a similar and 
significant increase in Cu, Zn, Fe and Mg. This suggests that some cases with IBSPDC are 
associated with a disorder including heavy metals, especially Cu, Zn, and Fe metabolism, 
and some metal-binding proteins. Even at low levels, Fe and Cu can catalyze a Fenton 
reaction, producing highly reactive hydroxyl radicals. Excessive amounts of Cu can be a 
directly neurotoxic factor and also damage neurons by producing reactive oxygen in 
neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and 
amyotrophic lateral sclerosis [9–11]. 
Pathological and biochemical analyses at autopsy are needed for further evaluation. In 
the study we could not recognize whether metals in the CSF are free or are derived from 
metal-binding proteins such as superoxide dismutase-1 and metallothioneins (MT). The 
high levels of metals in the CSF do not necessarily reflect correctly the pathophysiological 
mechanisms in the brain; however, this feature of the CSF provides some novel aspects of  
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the diseases. CSF of more numerous and clinically variable cases with IBSPDC should be 
examined in other races to clarify the common pathophysiological features. 
We have detected high levels of Cu, Zn, Fe and Mg in the CSF of 3 patients with 
IBSPDC in Japan. There is no specific and effective treatment for IBSPDC at present, and 
the progression of the disease is accelerated with age. MT is a small (7 kDa), metal-
binding (4 Cu and 3 Zn per molecule) protein that scavenges reactive oxygen species [10]. 
The study of CSF may provide a clue regarding a common pathway of IBSPDC including 
the metabolism of Cu, Zn, Fe and Mg and appropriate treatments including metal-
chelating agents such as ammonium tetrathiomolybdate, a Cu-chelating agent [11], and 
metal-binding proteins such as MT [10]. 
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Table 1. Levels of metals in CSF 
 Age  Ca  (mg/l)  Mg  (mg/l)** Fe  (μg/l)** Cu  (μg/l)** Zn  (μg/l)*   Mn (μg/l) 
Patient 1  26  45.0  49.1  418  33.9  08.00 2.10 
Patient 2  58  42.0  47.3  461  38.0  10.0  1.00 
Patient 3  76  49.0  48.2  458  40.1  22.2  2.10 
Average ± SD  53.3 ± 25.3  45.3 ± 3.51  48.2 ± 0.90  446 ± 23.7  37.3 ± 3.15  13.4 ± 7.69  1.73 ± 0.635 
Control (n = 15)  
Average ± SD 
 
48.4 ± 22.2 
 
41.1 ± 4.64 
 
29.6 ± 6.52 
 
238 ± 54.7 
 
10.2 ± 2.07 
 
5.30 ± 3.31 
 
1.90 ± 0.971 
The levels of Ca, Fe, Cu, Zn, Mg, and Mn in CSF of patients and controls (n = 13). Statistical analysis was performed 
using Mann-Whitney U test.  
* Significant difference, p < 0.05. ** Significant difference, p < 0.01. 
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Fig. 1. CT findings in patients. a CT findings in patient 1. A sagittal view shows a striking high density 
area in the basal ganglia and the dentate nuclei of the cerebellum. b CT findings in patient 2. An axial 
view shows a marked high density area in the basal ganglia and spots at various sites such as the 
pulvinar thalami, the subcortical area in the frontal lobe, and the border area of the cortex and white 
matter in the occipital lobe. c CT findings in patient 3. An axial view shows a striking high density area 
in the dentate nuclei of the cerebellum. 
 
 
 
Fig. 2. Comparative values of metals in the CSF. The average levels of Ca, Fe, Cu, Zn, Mg, and Mn in 
the CSF of patients and controls are shown to be set at the value of 100 (%) in the figure. Especially the 
values of Cu and Zn in patients are markedly higher compared to those of controls. * Significant 
difference, p <0.05. ** significant difference, p < 0.01. 
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